Four-year-old biotech Blend Therapeutics, launched with the scientific backing of MIT's Robert Langer and colleagues, is jettisoning its one-time lead drug program and focusing on a new top drug and platform tech with a $38 million C round. And it's taking a new name to help underscore the shift in focus.
Blend Therapeutics, which was founded by Omid Farokhzad and MIT's Robert Langer, has named Drew Fromkin as its new CEO.
Blend Therapeutics, a biotech with ties to MIT serial entrepreneur Robert Langer, has hauled in $21 million in new financing to flesh out a novel approach to cancer treatment.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
The startup biotech Blend Therapeutics rang in 2012 with seed cash and will now close out the year with a fresh injection of $16 million in B-round bucks budgeted to take this startup--one of the latest from the prolific scientist Robert Langer--right to the threshold of clinical development.
Serial biotech entrepreneurs Robert Langer and Omid Farokhzad are joining up with MIT's Dr. Stephen Lippard to launch a new drug developer--Blend Therapeutics--which will concentrate on the